Response Biomedical (RPBIF) 10-Q 13 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 29, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'RESPONSE BIOMEDICAL CORP	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	6,577,644
Amendment Flag	'false	'
Entity Central Index Key	'0000806888	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'

Consolidated_Balance_Sheets_Un

Consolidated Balance Sheets (Unaudited) (CAD)	Sep. 30, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Current	'		'
Cash and cash equivalents	1,152		2,080
Trade receivables, net	757		1,483
Other receivables	80		187
Inventories [note 5]	1,907		1,791
Prepaid expenses and other	268		211
Deferred financing costs [note 2]	193		'
Total current assets	4,357		5,752
Long-term prepaid expenses	93		93
Restricted deposits [note 7]	901		901
Property, plant and equipment	6,989		7,602
Total assets	12,340		14,348
Current	'		'
Accounts payable and accrued liabilities [notes 6 and 9]	2,860		1,897
Lease inducements - current portion [note 7]	171		173
Repayable leasehold improvement allowance - current portion [note 7]	402	[1]	370	[1]
Deferred revenue - current portion	148		255
Warrant liability [notes 4 and 8]	9,191		3,699
Total current liabilities	12,772		6,394
Lease inducements [note 7]	1,408		1,535
Repayable leasehold improvement allowance [note 7]	5,777	[1]	6,082	[1]
Deferred revenue	28		16
	19,985		14,027
Commitments and contingencies [notes 10 and 12]	'		'
Shareholders' deficit	'		'
Common shares [note 8]	99,852		99,289
Additional paid-in capital [note 8]	13,844		13,203
Deficit	-121,341		-112,171
Total shareholders' deficit	-7,645		321
	12,340		14,348
[1]	The Company received a repayable leasehold improvement for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the three and nine month periods ended September 30, 2013 amounted to $94,000 and $274,000 [2012 - $84,000 and $245,000]. Interest payments for the three and nine month periods ended September 30, 2013 amounted to $172,000 and $522,000 [2012 - $181,000 and $551,000].

Consolidated_Statements_of_Los

Consolidated Statements of Loss (Unaudited) (CAD)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
REVENUE	'	'	'	'
Product sales [note 11]	2,088	2,679	8,397	8,699
Cost of sales [notes 5, 8, and 10]	1,363	1,940	4,934	5,540
Gross profit on product sales	725	739	3,463	3,159
EXPENSES [notes 8, 9, and 10]	'	'	'	'
Research and development	614	838	1,728	2,435
General and administrative	938	1,062	2,801	3,297
Sales and marketing	550	372	1,566	981
Total operating expenses	2,102	2,272	6,095	6,713
OTHER EXPENSES (INCOME)	'	'	'	'
Interest expense [note 7]	173	182	525	554
Interest income	-3	-4	-10	-19
Other income	'	'	-58	'
Income tax expense	12	'	27	'
Foreign exchange (gain) loss	38	95	-1	24
Unrealized loss on revaluation of warrant liability [note 4]	950	854	6,055	1,861
Total other expenses	1,170	1,127	6,538	2,420
Net loss and comprehensive loss for the period	-2,547	-2,660	-9,170	-5,974
Loss per common share - basic and diluted [note 8] (in Dollars per share)	-0.39	-0.41	-1.4	-0.93
Weighted average number of common shares outstanding - basic and diluted [note 8] (in Shares)	6,577,664	6,455,183	6,550,368	6,454,652

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity/(Deficit) (Unaudited) (CAD)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2011	99,276,000	12,590,000	-106,890,000	4,976,000
Balance (in Shares) at Dec. 31, 2011	6,453,873	'	'	'
Net loss	'	'	-5,281,000	-5,281,000
Net shares issued upon exercise of warrants	13,000	'	'	13,000
Net shares issued upon exercise of warrants (in Shares)	1,333	'	'	'
Stock-based compensation expense	'	613,000	'	613,000
Balance at Dec. 31, 2012	99,289,000	13,203,000	-112,171,000	321,000
Balance (in Shares) at Dec. 31, 2012	6,455,206	'	'	'
Net loss	'	'	-9,170,000	-9,170,000
Net shares issued upon exercise of warrants	563,000	'	'	563,000
Net shares issued upon exercise of warrants (in Shares)	122,458	'	'	'
Stock-based compensation expense	'	506,000	'	506,000
Restricted share units issued to settle a liability	'	135,000	'	135,000
Balance at Sep. 30, 2013	99,852,000	13,844,000	-121,341,000	-7,645,000
Balance (in Shares) at Sep. 30, 2013	6,577,664	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (CAD)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
OPERATING ACTIVITIES	'	'
Net loss for the period	-9,170	-5,974
Add (deduct) items not involving cash:	'	'
Depreciation of property, plant and equipment	750	853
Amortization of deferred lease inducements	-129	-127
Stock-based compensation	506	492
Unrealized loss on revaluation of warrant liability	6,055	1,861
Changes in non-cash working capital:	'	'
Trade receivables	726	336
Other receivables	107	-7
Inventories	-116	-133
Prepaid expenses and other	-57	24
Accounts payable and accrued liabilities	888	-1,357
Deferred revenue	-95	-105
Cash generated from (used in) operating activities	-535	-4,137
INVESTING ACTIVITIES	'	'
Purchase of property, plant and equipment	-115	-241
Cash used in investing activities	-115	-241
FINANCING ACTIVITIES	'	'
Repayment of repayable leasehold improvement allowance	-273	-245
Deferred financing costs	-5	'
Cash used in financing activities	-278	-245
Increase (decrease) in cash during the period	-928	-4,623
Cash and cash equivalents, beginning of period	2,080	7,355
Cash and cash equivalents, end of period	1,152	2,732

Note_1_Description_of_Business

Note 1 - Description of Business	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Business Description and Basis of Presentation [Text Block]	'
	1. DESCRIPTION OF BUSINESS
	Response Biomedical Corp. (the “Company”) was incorporated on August 20, 1980 under the predecessor to the Business Corporations Act (British Columbia). The Company’s wholly-owned US subsidiary, Response Point of Care Inc., was incorporated on November 9, 2012 in the State of Delaware. The Company is engaged in the research, development, commercialization and distribution of diagnostic technologies for the medical central-lab testing, point of care (POC) testing and on-site environmental testing markets. POC, on-site diagnostic tests (or assays) are simple, non-laboratory based tests performed using portable hand-held devices, compact desktop analyzers, single-use test cartridges and/or dipsticks. Since 1996, the Company has developed and commercialized a proprietary diagnostic system under the RAMP® brand name.
	The RAMP® System is a portable fluorescence immunoassay-based diagnostic technology that combines the performance of a clinical lab with the convenience of a dipstick test, establishing a new paradigm in diagnostic testing. Immunoassays are extremely sensitive and specific tests used to identify and measure small quantities of materials, such as proteins. A large variety of biological molecules and inorganic materials can be targeted. Accordingly, the RAMP® technology is applicable to multiple distinct market segments and many products within those segments. RAMP® tests are now commercially available for use in the early detection of heart attack, congestive heart failure, venous thromboembolism, influenza A+B, the respiratory syncytial virus, environmental detection of West Nile Virus, and biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin.

Note_2_Basis_of_Presentation_a

Note 2 - Basis of Presentation and Going Concern Uncertainty	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	2. BASIS OF PRESENTATION AND GOING CONCERN UNCERTAINTY
	These unaudited interim consolidated financial statements have been prepared by management in Canadian dollars in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required to be presented for complete financial statements. The accompanying unaudited consolidated financial statements reflect, in the opinion of management, all adjustments (which include reclassifications and normal recurring adjustments) necessary for a fair presentation of the results for the interim periods presented. The accompanying consolidated balance sheet at December 31, 2012 has been derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year then ended. The consolidated financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Annual Report on Form 10-K for the year ended December 31, 2012 and filed with the United States Securities and Exchange Commission (“SEC”) on March 15, 2013.
	Going Concern Uncertainty
	The accompanying financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and liabilities and the settlement of commitments in the normal course of business. During the nine months ended September 30, 2013, the Company has incurred a net loss of $9.2 million and has had negative cash flows from operations of $0.5 million. As of September 30, 2013, the Company had a cash balance of $1.2 million, an accumulated deficit of $121.3 million, a shareholders’ deficit of $7.6 million, and a negative working capital balance of $8.4 million. In addition, the Company has various operating leases and purchase commitments for inventory (refer to note 10). Included in current liabilities is a warrant liability in the amount of $9.2 million that is required to be measured at fair value and is presented as a current liability in accordance with Accounting Standards Codification Topic 815 – Derivatives and Hedging (“ASC 815”). Each warrant may only be exercised on a net cashless exercise basis and no warrant may be exercised at a time when the exercise price equals or exceeds the current market price meaning the potential settlement of any warrant does not require any cash disbursement. Without taking into account the warrant liability mentioned above, current assets exceed current liabilities by $0.8 million.
	The ability of the Company to continue as a going concern is uncertain and dependant on the Company’s ability to obtain additional financing to fund ongoing operations. Management has, thus far, financed the operations through a series of equity financings. On November 7, 2013 the Company’s shareholders approved a brokered and non-brokered private placement of 1,273,117 subscription receipts (the “Subscription Receipts”) at a price of $2.45 for aggregate gross proceeds of $3.1 million (the “Private Placement”). The Company has incurred financing costs of approximately $0.4 million, of which $0.2 million have been deferred and capitalized as at September 30, 2013. Net proceeds from the financing are expected to be approximately $2.7 million. Each Subscription Receipt automatically entitles the holder to receive one unit. Each unit consists of one common share and one-half of one warrant to purchase one common share. Each whole warrant has a term of 36 months and an exercise price of $3.58. Management is actively attempting to secure additional commercial debt and will continue, as appropriate, to seek other sources of financing, including equity and debt, on favorable terms however, there can be no assurance that the Company will be able to secure such additional financing. Management believes that with the Private Placement noted above, based on the current level of operations, and excluding out of the ordinary cash management measures, the Company’s cash and cash equivalents balances, including cash generated from operations, will be sufficient to meet the anticipated cash requirements up to the second half of 2014. If additional financing is not obtained, we will be required to reduce or restructure operations or we may be required to cease operations. In view of these conditions, there is substantial doubt over the Company’s ability to continue as a going concern as it is dependent on additional financing and ultimately achieving profitable operations, the outcome of which cannot be predicted at this time. The consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.
	Stock Consolidation
	On June 19, 2012, the Company’s shareholders authorized a 20 to 1 consolidation of its issued and outstanding common shares (the “Consolidation”). The Company’s Board of Directors determined to proceed with the Consolidation on August 16, 2012 that became effective on September 24, 2012. All references to common shares, common shares outstanding, weighted-average number of shares outstanding, and per share amounts in these consolidated financial statements and notes to consolidated financial statements have been restated to reflect the Consolidation. In addition, references to stock options have also been restated to reflect the Consolidation. The number of stock options available for grant, exercised, and outstanding have been consolidated on the basis of every twenty (20) stock options being consolidated into one (1) stock option and the exercise price of each stock option has been multiplied by twenty (20) to account for the consolidation. Finally, as a result of the Consolidation, the number of shares each common share purchase warrant can purchase was reduced from one (1) to one-twentieth (1/20th) and the exercise price was adjusted to $1.492 per whole common share.

Note_3_Recent_Accounting_Prono

Note 3 - Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	'
	3. RECENT ACCOUNTING PRONOUNCEMENTS
	In February 2013, the Financial Accounting Standards Board issued updated authoritative guidance requiring entities to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under GAAP to be reclassified in its entirety to net income. For other amounts that are not required under GAAP to be reclassified in their entirety from accumulated other comprehensive income to net income in the same reporting period, an entity is required to cross-reference other disclosures required under GAAP that provide additional detail about those amounts. The Company adopted this guidance effective January 1, 2013. The adoption of this standard did not have a material effect on the Company’s consolidated financial statements.

Note_4_Fair_Value_Measurements

Note 4 - Fair Value Measurements

9 Months Ended

Sep. 30, 2013

Fair Value Disclosures [Abstract]

'

Fair Value Disclosures [Text Block]

'

4. FAIR VALUE MEASUREMENTS

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (“exit price”) in an orderly transaction between market participants at the measurement date. Fair value measurements of financial instruments are determined by using a fair value hierarchy that prioritizes the inputs to valuation techniques into three levels according to the relative reliability of the inputs used to estimate the fair values.

The three levels of inputs used to measure fair value are as follows:

Level 1 – Unadjusted quoted prices in active markets for identical financial instruments;

Level 2 – Inputs other than quoted prices that are observable for the financial instrument either directly or indirectly; and

Level 3 – Inputs that are not based on observable market data.

In determining fair value measurements, the Company uses the most observable inputs when available.

For certain of the Company’s financial instruments, including cash and cash equivalents, trade receivables, other receivables, and accounts payable and accrued liabilities the carrying amounts approximate fair values due to their short-term nature. The carrying value of the restricted deposits approximates its fair value due to the nature of the cash deposit. The fair value of the repayable leasehold improvement allowance approximates its carrying value as the fixed interest rate of 11% is considered to approximate the current market rate.

The fair value hierarchy level at which a financial instrument is categorized is determined on the basis of the lowest level input that is significant to the fair value measurement (in thousands):

Financial Instrument carried at fair value as of September 30, 2013

Level 1

Level 2

Level 3

Total

Liabilities

$

$

$

$

Warrant Liability

-

-

9,191

9,191

As of September 30, 2013, the warrant liability is recorded at its fair value of $9.2 million. The Company reassesses the fair value of the common stock warrants at each reporting date utilizing a Black-Scholes pricing model. Inputs used in the pricing model include estimates of stock price volatility, contractual term of the warrant, and risk-free interest rate (refer to note 8[e]). The computation of expected volatility was based on the historical volatility of the Company’s stock. A small change in the estimates used in the Black-Scholes pricing model may have a relatively large change in the estimated valuation of the common stock warrants.

The following table presents the changes in fair value of the Company’s total Level 3 financial liabilities for the nine month period ended September 30, 2013 (in thousands):

Balance at

Unrealized loss

Exercise of Warrants

Balance at

31-Dec-12

30-Sep-13

Warrant Liability

$

3,699

$

6,055

$

(563

)

$

9,191

The unrealized loss recorded during the nine months ended September 30, 2013 is the result of an increase, from December 31, 2012, in the market price of the Company’s shares, which is an input into the pricing model noted above.

Quantitative information about unobservable inputs used in Level 3 fair value measurements is presented below:

Valuation Technique

Unobservable Input

As at September

As at December 31,

30, 2013

2012

Warrant Liability

Option Model

Stock Price Volatility

132

%

128

%

A 5% increase in stock price volatility would result in a corresponding $140,000 increase to the Warrant Liability ($100,000 – December 31, 2012) and a 5% decrease in stock price volatility would result in a $140,000 decrease to the Warrant Liability ($100,000 – December 31, 2012).

Note_5_Inventories

Note 5 - Inventories	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	5. INVENTORIES
	Inventories are comprised of the following (in thousands):
		30-Sep-13		31-Dec-12
			$		$
	Raw materials		891		684
	Work in progress		308		381
	Finished goods		708		726
			1,907		1,791
	The carrying value of inventory as of September 30, 2013 includes a provision for lower of cost and market value on the Company’s reader inventory in the amount $79,000 [December 31, 2012 - $81,000]. The carrying value of inventory as of September 30, 2013 also includes a writedown and a provision for expired and damaged inventory in the amount of $52,000 [December 31, 2012 - $59,000]. For the three and nine month periods ended September 30, 2013, inventory write-down charges/(recoveries) were ($6,000) and $157,000 [2012 - $48,000 and $138,000].

Note_6_Accounts_Payable_and_Ac

Note 6 - Accounts Payable and Accrued Liabilities	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
	Accounts payable and accrued liabilities comprise (in thousands):
		30-Sep-13		31-Dec-12
			$		$
	Trade accounts payable		1,280		521
	Employee related accounts payable and accrued liabilities		831		684
	Royalties		164		166
	Other accrued liabilities		585		526
			2,860		1,897
	Accounts payable and accrued liabilities include $188,000 of deferred financing costs and $22,000 of additions to property, plant, and equipment as at September 30, 2013. These amounts have been excluded from cash used in financing activities and cash used in investing activities respectively on the statements of cash flows for the nine months ended September 30, 2013 as the cash had not been disbursed. Consequently, both amounts have been excluded from cash used in operating activities.

Note_7_Lease_Inducements

Note 7 - Lease Inducements	9 Months Ended
	Sep. 30, 2013
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]	'
Other Liabilities Disclosure [Text Block]	'
	7. LEASE INDUCEMENTS
	Lease agreements entered into by the Company for its offices provides for lease inducements to be provided by the landlord to the Company which are summarized as follows (in thousands):
		30-Sep-13		31-Dec-12
			$		$
	Current Portion
	Rent-free inducement [i]		56		58
	Non-repayable leasehold improvement allowance [ii]		115		115
			171		173
	Repayable leasehold improvement allowance [iii]		402		370
	Total Current Portion		573		543
	Long-Term Portion
	Rent-free inducement [i]		452		493
	Non-repayable leasehold improvement allowance [ii]		956		1,042
			1,408		1,535
	Repayable leasehold improvement allowance [iii]		5,777		6,082
	Total Long-Term Portion		7,185		7,617
	Total		7,758		8,160
	During the year ended December 31, 2007, the Company entered into a 15 year facility lease agreement [note 10[c][i]]. The agreement provides for lease inducements to be provided by the landlord to the Company which are summarized as follows:
	The lease inducements disclosed on the consolidated balance sheets as a result of these benefits is comprised of the following:
	[i]      In 2007, the Company entered into a long-term facility lease agreement that included an eight and one half month rent-free period from May 17, 2007 to February 1, 2008. The lease inducement benefit arising from the rent-free period is being amortized on a straight-line basis over the term of the operating lease as a reduction to rental expense. Amortization for the three and nine month periods ended September 30, 2013 amounted to a reduction of rental expense $14,000 and $41,000 [2012 - $14,000 and $41,000].
	[ii]      The Company received a non-repayable allowance for an amount of $1.7 million for expenditures related to general upgrades to the facility. The lease inducement benefit arising from the non-repayable leasehold improvement allowance is being amortized on a straight-line basis over the balance of the term of the lease beginning April 1, 2008 as a reduction to rental expense. Amortization for the three and nine month periods ended September 30, 2013 amounted to a reduction of rental expense of $29,000 and $86,000 [2012 - $29,000 and $86,000].
	[iii]     The Company received a repayable leasehold improvement for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the three and nine month periods ended September 30, 2013 amounted to $94,000 and $274,000 [2012 - $84,000 and $245,000]. Interest payments for the three and nine month periods ended September 30, 2013 amounted to $172,000 and $522,000 [2012 - $181,000 and $551,000].
	To secure the lease, the Company is maintaining a security deposit with the landlord in the form of an irrevocable letter of credit in the amount of $871,000 collateralized by a term deposit with a market value of $871,000 that is presented as part of restricted deposits in the long-term asset section of the balance sheets.

Note_8_Share_Capital_and_Addit

Note 8 - Share Capital and Additional Paid-in Capital	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	8. SHARE CAPITAL AND ADDITIONAL PAID-IN CAPITAL
	[a]     Authorized - Unlimited common shares without par value.
	[b]      Issued
	The Company’s issued and outstanding common shares were consolidated on the basis of every twenty (20) common shares being consolidated into one (1) common share during 2012. Refer to note 2 for discussion of the effect of this stock consolidation.
	The Company closed a shareholder rights offering on December 29, 2011 consisting of 4,506,395 units, with each unit consisting of one common share and one common share purchase unit at a price of $1.492 per share for total gross proceeds of $6,723,542.
	Each warrant entitles the holder thereof to purchase one-twentieth common share of the Company at a price of $1.492 per whole common share for a period of five years after the closing date. Each warrant may only be exercised on a net cashless exercise basis, and no warrant may be exercised at a time when the exercise price equals or exceeds the current market price. Subject to certain exceptions, the holders of the warrants will be entitled to full ratchet anti-dilution price protection for a period of two years after the closing of the offering and volume weighted anti-dilution price protection thereafter. The Company accounts for warrants under the authoritative guidance on accounting for derivative financial instruments. As a result of these price protection features, the Company has classified these warrants on the accompanying balance sheet as a liability that is revalued at each balance sheet date subsequent to the initial issuance in accordance with ASC 815. On the date of issuance, the Company used the Black-Scholes pricing model to value these warrants based on an assumed risk-free interest rate of 1.18%, estimated stock price volatility of 110%, and a contractual term to expiry of five years. Subsequent changes in the fair value of the warrants between the date of issuance and the balance sheet date are reflected in the consolidated statements of loss and comprehensive loss as unrealized gain (loss) on revaluation of warrant liability.
	The net proceeds of the rights offering were $6,037,803 after deducting issue costs of $685,739. Of these net proceeds, $2,330,921 was allocated to common shares and $3,706,882 was allocated to the warrants. Further, of this amount allocated to the warrants, $4,127,888 was recorded as warrant liability and $421,008 of issue costs allocated to the warrants was expensed to warrant issue costs on the consolidated statements of loss and comprehensive loss.
	[c]      Stock option plan
	At the Annual General Meeting held September 3, 2008, the Company’s shareholders approved a new stock option plan (“2008 Plan”). Under the plan, the Company may grant options to purchase common shares in the Company to employees, directors, officers and consultants of the Company. The exercise price of the options is determined by the Board but is equal to the fair market value of the common shares at the grant date. The Company estimates the fair value of options on the date of the grant. The options vest over the requisite service period in accordance with terms as determined by the Board, typically over four years. Stock options expire no later than ten years from the date of grant.
	At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders’ approved a change to the maximum number of the Company’s authorized shares under its 2008 stock option plan permitting a maximum of 20% of the issued and outstanding common shares outstanding at any point in time.
	Of the 1,315,532 stock options authorized for grant under the 2008 Plan as at September 30, 2013, 172,763 stock options are available for grant.
	Stock option transactions and the number of stock options outstanding are summarized below:
			Number of optioned			Weighted average
			common shares			exercise price
			#				$
	Balance at December 31, 2012			989,064			1.98
	Options granted			207,670			3.09
	Options forfeited			(53,402	)		2.24
	Options expired			(563	)		133.49
	Balance, September 30, 2013			1,142,769			2.11
	At September 30, 2013, the following stock options were outstanding:
		Range of					Number of			Weighted average			Weighted average		Number of options		Weighted average
		exercise price					shares under			remaining			exercise price		currently		exercise price
							option			contractual life					exercisable
			$				#			(years)				$	#			$
			1.02	-	1.6			509,316			8.9			1.53		143,557		1.57
					2.2			430,878			8.51			2.2		343,138		2.2
			3	-	3.10			198,270			9.47			3.09		-		-
			6.8	-	8.2			2,036			2.35			7.75		666		7.86
			23	-	24			2,269			0.81			23.38		1,782		23.48
			1.02	-	24			1,142,769			8.82			2.11		489,143		2.1
	The fair value of each stock award is estimated on the grant date using the Black-Scholes option-pricing model based on the assumptions noted in the following table:
	Nine Months Ended September 30,		2013			2012
	Risk-free interest rates			1.66	%		1.69	%
	Expected dividend yield			0	%		0	%
	Expected life (in years)			5.74			5.95
	Expected volatility			123	%		113	%
	Fair value per stock option			$2.68			$1.59
	[d]      Restricted share unit plan
	At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders approved a new restricted share unit plan (“RSU Plan”). Under the plan, the Company may grant Restricted Share Units (“RSUs”) to employees, directors, and eligible consultants which entitle each participant to either one common share of the Company on a time vested basis or a cash payout equal to the number of vested RSUs multiplied by the then current market value of the RSUs. The fair market value of the RSUs is determined based upon the number of RSUs granted and the quoted closing price of the Company’s stock on the trading day immediately preceding the date of determination. The duration of the vesting period and other vesting terms applicable to the grant of the RSUs shall be determined by the Board.
			Number			Weighted average
			of RSUs			grant price
			#
	Balance at December 31, 2012			-			-
	RSUs granted			53,258			2.54
	Balance, September 30, 2013			53,258			2.54
	The restricted share units that were granted during the nine month period ended September 30, 2013 were to settle a director compensation liability that was recorded in Accounts payable and accrued liabilities. The $135,000 liability has been excluded from the change in accounts payable and accrued liabilities on the statement of cash flows.
	Of the 164,441 RSUs authorized for grant under the RSU Plan as at September 30, 2013, 111,183 RSUs are available for grant.
	[e]     Deferred share unit plan
	At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders approved a new non-employee director deferred share unit plan (“DSU Plan”). A Deferred Share Unit (“DSU”) is a right granted to non-employee directors which entitle each participant to either one common share of the Company on a time vested basis or a cash payout equal to the number of DSUs multiplied by the then current market value of the DSUs. The fair market value of the DSU’s is determined based upon the number of DSUs granted and the quoted price of the Company’s stock on the trading day immediately preceding the determination date. The duration of the vesting period and other vesting terms applicable to the grant of the DSU’s shall be determined by the Board.
	Of the 164,441 DSUs authorized for grant under the DSU Plan as at September 30, 2013, all are available for grant.
	[f] Share-based compensation
	The following table shows share-based compensation allocated by type of cost (in thousands):
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2013			2012			2013			2012
				$			$			$			$
	Cost of sales			8			3			24			19
	Research and development			12			8			34			38
	General and administrative			160			75			422			430
	Sales and marketing			10			3			26			5
				190			89			506			492
	As of September 30, 2013, the total compensation expense to be recognized in future periods related to stock options granted amounts to $913,000, which is expected to be recognized over a weighted average service period of 2.26 years.
[g] Common share purchase warrants
Common share purchase warrant transactions and the number of warrants outstanding are summarized below:
		Number of			Weighted average
		warrants			exercise price
		#				$
Balance, December 31, 2012			89,976,289			0.0746
Exercise of warrants			(3,872,545	)		0.0746
Balance, September 30, 2013			86,103,744			0.0746
As discussed in note 2, each warrant entitles the holder thereof to purchase 1/20th of a common share of the Company at a price of $1.492 per whole common share.
The estimated fair value of warrants issued is reassessed at each balance sheet date using the Black-Scholes option pricing model. The following assumptions were used to value the warrants on the following balance sheet dates:
		30-Sep-13			31-Dec-12
Risk-free interest rates			1.69	%		1.33	%
Expected dividend yield			0	%		0	%
Expected life (in years)			3.25			4
Expected volatility			132	%		128	%
Fair value of warrant		$	0.1067		$	0.0411
[h]     Earnings per common share
Basic net income per share is computed by dividing the net income attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income attributable to common shareholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding using the treasury stock method. Dilutive potential common shares outstanding include outstanding warrants, stock options, and restricted share units.
86,103,744 warrants, 1,142,769 stock options and 53,258 restricted share units have been excluded from the computation of diluted earnings per share for the three and nine month periods ended September 30, 2013 as the Company has incurred a net loss during the periods and their inclusion would be anti-dilutive to our loss per share (2012 - 89,985,289 warrants and 969,000 stock options were excluded).

Note_9_Related_Party_Transacti

Note 9 - Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	9. RELATED PARTY TRANSACTIONS
	During the three and nine month periods ended September 30, 2012, the Company incurred consulting fees to a director of $25,000 and $100,000, respectively. There were no such fees incurred during the three and nine month periods ended September 30, 2013. These consulting fees have been fully paid as of September 30, 2013.
	All related party transactions are recorded at their exchange amounts, established and agreed between the related parties.

Note_10_Commitments

Note 10 - Commitments	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block Supplement [Abstract]	'
Commitments Disclosure [Text Block]	'
	10. COMMITMENTS
	[a]     License agreements
	[i]     The Company entered into a non-exclusive license agreement, effective July 2005, as amended September 2008, to use and sublicense certain technology (“Technology”) for one of the Company’s cardiac tests. In consideration for these rights, the Company paid a non-refundable license issuance fee of $2,000,000 in the first two years after execution of the agreement and is required to pay quarterly royalties on the sale of products that incorporate the Technology. For the three and nine month periods ended September 30, 2013, the Company incurred an expense of $101,000 and $471,000 [2012 - $189,000 and $416,000] for royalties.
	[ii]     The Company entered into a non-exclusive license and supply agreement, effective September 30, 2009 to purchase certain proprietary materials and use related intellectual property to manufacture and sell lateral flow immunoassay products. In consideration for these rights, the Company is to pay a non-refundable, non-creditable license fee, of USD$85,000 in 17 equal quarterly payments of USD$5,000 commencing December 31, 2009. For the three and nine month periods ended September 30, 2013, the Company incurred an expense of $5,000 and $15,000 [2012 - $5,000 and $ 15,000] for license fees.
	All royalty and license fees incurred are included in cost of sales.
	[b]     Supply agreement
	The Company entered into a supply agreement, effective September 2003 for certain reagents for the Company’s RAMP® West Nile Virus Test. In addition to paying for the reagent purchased, the Company is required to pay the supplier semi-annual royalties equal to 10% of net revenue generated from the sale of the Company’s RAMP® West Nile Virus Test. The initial term of the agreement was three years from the effective date and is automatically renewed for successive periods of one year until either party terminates the agreement. For the three and nine month periods ended September 30, 2013, the Company incurred an expense of $12,000 and $47,000 [2012 - $4,000 and $33,000] for royalties to the supplier. These royalties are included in cost of sales.
	[c]     Lease agreements
	[i]     The Company entered into a long-term agreement to lease a single tenant 46,000 square foot facility to house all of the Company’s operations beginning March 2008. Rent is payable from February 1, 2008 to January 31, 2023. The Company is required to pay the landlord total gross monthly payments of approximately $170,000, which is comprised of base rent, administrative and management fees, estimated property taxes and repayments of the repayable leasehold improvement allowance [note 7[iii]].
	For the three and nine month periods ended September 30, 2013, $201,000 and $606,000 [2012 - $196,000 and $583,000] was incurred for expenses related to base rent, administrative and management fees, estimated property taxes offset by amortization of both the rent-free inducement [note 7[i]] and non-repayable leasehold improvement allowance [note 7[ii]]. These expenses are allocated to cost of sales, research and development, general and administrative, and sales and marketing expenses.
	[d] Purchase commitments
	As of September 30, 2013, the Company has outstanding purchase commitments of $1,084,000 to purchase inventory over the next twelve months. In addition, the Company has certain commitments to purchase on hand inventory with suppliers in the event of termination of various supply agreements. These commitments are not fixed and are dependent on the level of inventory at the time of termination.
	[e] Indemnification of directors and officers
	Under the Articles of the Company, applicable law and agreements with its directors and officers, the Company, in circumstances where the individual has acted legally, honestly and in good faith, may, or is required to indemnify its directors and officers against certain losses. The Company's liability in respect of the indemnities is not limited. The maximum potential of the future payments is unlimited. However, the Company maintains appropriate liability insurance that limits the exposure and enables the Company to recover any future amounts paid, less any deductible amounts pursuant to the terms of the respective policies, the amounts of which are not considered material.
	[f] Indemnification of third parties
	The Company has entered into license and research agreements with third parties that include indemnification provisions that are customary in the industry. These indemnifications generally require the Company to compensate the other party for certain damages and costs incurred as a result of third party claims or damages arising from these transactions. The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount that it could be required to pay. To date, the Company has not made any indemnification payments under such agreements and no amount has been accrued in these consolidated financial statements with respect to these indemnification obligations.

Note_11_Segment_Information

Note 11 - Segment Information	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	11. SEGMENTED INFORMATION
	The Company operates primarily in one business segment, the research, development, commercialization and distribution of diagnostic technologies, with primarily all of its assets and operations located in Canada. The Company’s revenues are generated from product sales primarily in China, the United States, Europe, Asia (excluding China) and Canada. Expenses are primarily incurred from purchases made from suppliers in Canada and the United States.
	Customers that represent a concentration risk are those customers who represent 10% or greater of our total revenue. For the three month period ended September 30, 2013, $1.5 million (71%) in product sales was generated from three customers [2012 - $2.0 million (75%) from one customer]. For the nine month period ended September 30, 2013, $5.1 million (61%) in product sales was generated from two customers [2012 - $5.8 million (66%) from one customer] of whom one customer represents $3.8 million (46%).
	Product sales by customer location were as follows (in thousands):
		Three months ended				Nine months ended
		September 30,				September 30,
		2013		2012		2013		2012
			$		$		$		$
	China		1,231		2,028		5,149		5,763
	United States		298		151		1,456		804
	Asia (excluding China)		107		27		466		620
	Europe		303		221		883		694
	Canada		4		11		33		27
	Other		145		241		410		791
	Total		2,088		2,679		8,397		8,699
	Product sales by type of product were as follows (in thousands):
		Three months ended				Nine months ended
		September 30,				September 30,
		2013		2012		2013		2012
			$		$		$		$
	Cardiovascular		1,852		2,559		7,088		8,012
	Bio-defense products		69		65		320		289
	Infectious Diseases		1		-		456		47
	West Nile Virus		166		55		533		351
	Total		2,088		2,679		8,397		8,699

Note_12_Contigencies

Note 12 - Contigencies	9 Months Ended
	Sep. 30, 2013
Loss Contingency [Abstract]	'
Contingencies Disclosure [Text Block]	'
	12. CONTINGENCIES
	In 2009, the Company sold approximately $0.9 million of RAMP® 200 readers and accessories to Roche Diagnostics. On September 2, 2011, the Company received notification from Roche Diagnostics that they had terminated, effective September 30, 2011, the sales and distribution agreement between Roche Diagnostics and the Company dated September 25, 2008. Roche Diagnostics terminated the agreement because the Company had not obtained the necessary approvals from the U.S. Food and Drug Administration (FDA) to permit Roche Diagnostics to market certain of the Company’s cardiovascular tests for use in point of care settings in the United States using the RAMP® 200 Reader. On November 1, 2012, Roche Diagnostics advised the Company that they believe the Company has an obligation to repurchase the unsold products remaining in Roche Diagnostics’ inventory. The Company believes Roche Diagnostics’ claim does not have legal merit and no provision has been recognized. However, in the event the Company is required to re-purchase the products, it believes that any loss contingency would be reduced by the Company’s ability to re-sell the purchased products.

Note_13_Comparative_Informatio

Note 13 - Comparative Information	9 Months Ended
	Sep. 30, 2013
Policy Text Block [Abstract]	'
Comparability of Prior Year Financial Data, Policy [Policy Text Block]	'
	13. COMPARATIVE INFORMATION
	Certain comparative figures in the notes to the financial statements have been reclassified from the amounts previously reported to conform to the presentation in the current year.

Note_14_Subsequent_Events

Note 14 - Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	14. SUBSEQUENT EVENTS
	On November 7, 2013, the Company held a special general meeting where the shareholders of the Company approved the brokered and non-brokered Private Placement of 1,273,117 Subscription Receipts priced at $2.45 for aggregate gross proceeds of $3.1 million. Of the total number of Subscription Receipts, the Company’s largest shareholder, OrbiMed, subscribed for 816,325 Subscription Receipts for gross proceeds of $2 million. Refer to the “Going Concern Uncertainty” discussion in note 2 for a description of the Private Placement.

Note_4_Fair_Value_Measurements1

Note 4 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value, by Balance Sheet Grouping [Table Text Block]	'
			Level 1				Level 2				Level 3			Total
	Liabilities			$				$				$			$
	Warrant Liability			-				-				9,191			9,191
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	'
			Balance at				Unrealized loss				Exercise of Warrants			Balance at
			31-Dec-12											30-Sep-13
	Warrant Liability		$	3,699			$	6,055			$	(563	)	$	9,191
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]	'
		Valuation Technique	Unobservable Input		As at September				As at December 31,
					30, 2013				2012
	Warrant Liability	Option Model	Stock Price Volatility			132	%			128	%

Note_5_Inventories_Tables

Note 5 - Inventories (Tables)	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
		30-Sep-13		31-Dec-12
			$		$
	Raw materials		891		684
	Work in progress		308		381
	Finished goods		708		726
			1,907		1,791

Note_6_Accounts_Payable_and_Ac1

Note 6 - Accounts Payable and Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	'
		30-Sep-13		31-Dec-12
			$		$
	Trade accounts payable		1,280		521
	Employee related accounts payable and accrued liabilities		831		684
	Royalties		164		166
	Other accrued liabilities		585		526
			2,860		1,897

Note_7_Lease_Inducements_Table

Note 7 - Lease Inducements (Tables)	9 Months Ended
	Sep. 30, 2013
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]	'
Lease Inducements [Table Text Block]	'
		30-Sep-13		31-Dec-12
			$		$
	Current Portion
	Rent-free inducement [i]		56		58
	Non-repayable leasehold improvement allowance [ii]		115		115
			171		173
	Repayable leasehold improvement allowance [iii]		402		370
	Total Current Portion		573		543
	Long-Term Portion
	Rent-free inducement [i]		452		493
	Non-repayable leasehold improvement allowance [ii]		956		1,042
			1,408		1,535
	Repayable leasehold improvement allowance [iii]		5,777		6,082
	Total Long-Term Portion		7,185		7,617
	Total		7,758		8,160

Note_8_Share_Capital_and_Addit1

Note 8 - Share Capital and Additional Paid-in Capital (Tables)	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
			Number of optioned			Weighted average
			common shares			exercise price
			#				$
	Balance at December 31, 2012			989,064			1.98
	Options granted			207,670			3.09
	Options forfeited			(53,402	)		2.24
	Options expired			(563	)		133.49
	Balance, September 30, 2013			1,142,769			2.11
Schedule of Share-based Compensation, Activity [Table Text Block]	'
		Range of					Number of			Weighted average			Weighted average		Number of options		Weighted average
		exercise price					shares under			remaining			exercise price		currently		exercise price
							option			contractual life					exercisable
			$				#			(years)				$	#			$
			1.02	-	1.6			509,316			8.9			1.53		143,557		1.57
					2.2			430,878			8.51			2.2		343,138		2.2
			3	-	3.10			198,270			9.47			3.09		-		-
			6.8	-	8.2			2,036			2.35			7.75		666		7.86
			23	-	24			2,269			0.81			23.38		1,782		23.48
			1.02	-	24			1,142,769			8.82			2.11		489,143		2.1
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	Nine Months Ended September 30,		2013			2012
	Risk-free interest rates			1.66	%		1.69	%
	Expected dividend yield			0	%		0	%
	Expected life (in years)			5.74			5.95
	Expected volatility			123	%		113	%
	Fair value per stock option			$2.68			$1.59
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	'
			Number			Weighted average
			of RSUs			grant price
			#
	Balance at December 31, 2012			-			-
	RSUs granted			53,258			2.54
	Balance, September 30, 2013			53,258			2.54
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2013			2012			2013			2012
				$			$			$			$
	Cost of sales			8			3			24			19
	Research and development			12			8			34			38
	General and administrative			160			75			422			430
	Sales and marketing			10			3			26			5
				190			89			506			492
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
			Number of			Weighted average
			warrants			exercise price
			#				$
	Balance, December 31, 2012			89,976,289			0.0746
	Exercise of warrants			(3,872,545	)		0.0746
	Balance, September 30, 2013			86,103,744			0.0746
Estimated Fair Value of Warrants Issued, Valuation Assumptions [Table Text Block]	'
			30-Sep-13			31-Dec-12
	Risk-free interest rates			1.69	%		1.33	%
	Expected dividend yield			0	%		0	%
	Expected life (in years)			3.25			4
	Expected volatility			132	%		128	%
	Fair value of warrant		$	0.1067		$	0.0411

Note_11_Segment_Information_Ta

Note 11 - Segment Information (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	'
		Three months ended				Nine months ended
		September 30,				September 30,
		2013		2012		2013		2012
			$		$		$		$
	China		1,231		2,028		5,149		5,763
	United States		298		151		1,456		804
	Asia (excluding China)		107		27		466		620
	Europe		303		221		883		694
	Canada		4		11		33		27
	Other		145		241		410		791
	Total		2,088		2,679		8,397		8,699
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
		Three months ended				Nine months ended
		September 30,				September 30,
		2013		2012		2013		2012
			$		$		$		$
	Cardiovascular		1,852		2,559		7,088		8,012
	Bio-defense products		69		65		320		289
	Infectious Diseases		1		-		456		47
	West Nile Virus		166		55		533		351
	Total		2,088		2,679		8,397		8,699

Note_2_Basis_of_Presentation_a1

Note 2 - Basis of Presentation and Going Concern Uncertainty (Details) (CAD)	3 Months Ended		9 Months Ended		12 Months Ended					0 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2016	Jun. 30, 2013	Dec. 31, 2011	Dec. 29, 2011	Nov. 07, 2013	Nov. 07, 2013
										Subsequent Event [Member]	Subsequent Event [Member]
										Gross [Member]
Note 2 - Basis of Presentation and Going Concern Uncertainty (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net Income (Loss) Attributable to Parent	-2,547,000	-2,660,000	-9,170,000	-5,974,000	-5,281,000	'	'	'	'	'	'
Net Cash Provided by (Used in) Operating Activities	'	'	-535,000	-4,137,000	'	'	'	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	1,152,000	2,732,000	1,152,000	2,732,000	2,080,000	'	'	7,355,000	'	'	'
Retained Earnings (Accumulated Deficit)	-121,341,000	'	-121,341,000	'	-112,171,000	'	'	'	'	'	'
Stockholders' Equity Attributable to Parent	-7,645,000	'	-7,645,000	'	321,000	'	'	4,976,000	'	'	'
Working Capital Deficit	-8,400,000	'	-8,400,000	'	'	'	'	'	'	'	'
Derivative Liability, Current (in Dollars)	9,191,000	'	9,191,000	'	3,699,000	'	'	'	'	'	'
Working Capital if Excluding Warrant Liability	-800,000	'	-800,000	'	'	'	'	'	'	'	'
Number of Subscription Receipts Issued, Private Placement	'	'	'	'	'	'	'	'	'	'	1,273,117
Subscription Receipts Issuance Price (in Dollars per Share)	'	'	'	'	'	'	'	'	'	'	2.45
Proceeds from Issuance of Private Placement (in Dollars)	'	'	'	'	'	'	'	'	'	3,100,000	2,700,000
Deferred Finance Costs, Gross	200,000	'	200,000	'	'	'	'	'	'	'	400,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)	'	'	'	'	'	'	'	'	'	'	3.58
Warrant Exercise Price Per Whole Common Share (in Dollars per share)	'	'	'	'	'	1.492	1.492	'	1.492	'	'

Note_4_Fair_Value_Measurements2

Note 4 - Fair Value Measurements (Details) (CAD)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Fair Value Disclosures [Abstract]	'	'
Fair Value Inputs, Discount Rate	11.00%	'
Derivative Liability, Current (in Dollars)	9,191	3,699

Note_4_Fair_Value_Measurements3

Note 4 - Fair Value Measurements (Details) - Financial Instrument Carried at Fair Value (CAD)	Sep. 30, 2013	Dec. 31, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Warrant Liability	9,191,000	3,699,000
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Warrant Liability	0	'
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Warrant Liability	0	'
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Warrant Liability	9,191,000	'

Note_4_Fair_Value_Measurements4

Note 4 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities (CAD)	3 Months Ended		9 Months Ended		12 Months Ended	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012	Dec. 29, 2011	Sep. 30, 2013
						Warrant [Member]	Warrant [Member]	Warrant [Member]	Warrant [Member]	Fair Value, Inputs, Level 3 [Member]
						Fair Value, Inputs, Level 3 [Member]	Fair Value, Inputs, Level 3 [Member]	Fair Value, Inputs, Level 3 [Member]
Note 4 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities [Line Items]	'	'	'	'	'	'	'	'	'	'
Warrant Liability	9,191,000	'	9,191,000	'	3,699,000	'	9,191	3,699	4,127,888	9,191,000
Warrant Liability	950,000	854,000	6,055,000	1,861,000	'	6,055	'	'	'	'
Warrant Liability	'	'	-563,000	'	-13,000	-563	'	'	'	'

Note_4_Fair_Value_Measurements5

Note 4 - Fair Value Measurements (Details) - Quantitative Information about Unobservable Inputs (Warranty Obligations [Member])	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Warranty Obligations [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Warrant Liability	'Option Model	'
Warrant Liability	132.00%	128.00%

Note_5_Inventories_Details

Note 5 - Inventories (Details) (CAD)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012
					Readers [Member]	Readers [Member]	Expired and Damaged [Member]	Expired and Damaged [Member]
Note 5 - Inventories (Details) [Line Items]	'	'	'	'	'	'	'	'
Inventory Valuation Reserves	'	'	'	'	79,000	81,000	52,000	59,000
Inventory Write-down	-6,000	48,000	157,000	138,000	'	'	'	'

Note_5_Inventories_Details_Inv

Note 5 - Inventories (Details) - Inventory (CAD)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory [Abstract]	'	'
Raw materials	891	684
Work in progress	308	381
Finished goods	708	726
	1,907	1,791

Note_6_Accounts_Payable_and_Ac2

Note 6 - Accounts Payable and Accrued Liabilities (Details) (CAD)	Sep. 30, 2013
Deferred Financing Costs [Member]	'
Note 6 - Accounts Payable and Accrued Liabilities (Details) [Line Items]	'
Accrued Liabilities and Other Liabilities	188,000
Additions to PPE [Member]	'
Note 6 - Accounts Payable and Accrued Liabilities (Details) [Line Items]	'
Accrued Liabilities and Other Liabilities	22,000

Note_6_Accounts_Payable_and_Ac3

Note 6 - Accounts Payable and Accrued Liabilities (Details) - Accounts Payable and Accrued Liabilities (CAD)	Sep. 30, 2013	Dec. 31, 2012
Accounts Payable and Accrued Liabilities [Abstract]	'	'
Trade accounts payable	1,280	521
Employee related accounts payable and accrued liabilities	831	684
Royalties	164	166
Other accrued liabilities	585	526
	2,860	1,897

Note_7_Lease_Inducements_Detai

Note 7 - Lease Inducements (Details) (CAD)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

181 Months Ended

3 Months Ended

9 Months Ended

69 Months Ended

181 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Apr. 30, 2023

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Apr. 30, 2023

Sep. 30, 2013

Lease Incentive One [Member]

Lease Incentive One [Member]

Lease Incentive One [Member]

Lease Incentive One [Member]

Lease Incentive Two [Member]

Lease Incentive Two [Member]

Lease Incentive Two [Member]

Lease Incentive Two [Member]

Lease Incentive Two [Member]

Lease Incentive Three [Member]

Lease Incentive Three [Member]

Lease Incentive Three [Member]

Lease Incentive Three [Member]

Lease Incentive Three [Member]

Lease Incentive Three [Member]

Letter of Credit [Member]

Letter of Credit [Member]

Monthly [Member]

Note 7 - Lease Inducements (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of Lease Incentives, Lessee

'

'

'

'

14,000

14,000

41,000

41,000

29,000

29,000

86,000

86,000

'

94,000

84,000

274,000

245,000

'

'

'

'

Allowance for Leasehold Improvement, Non-repayable

'

'

'

'

'

'

'

'

'

'

'

'

1,700,000

'

'

'

'

'

'

'

'

Allowance for Leasehold Improvement, Repayable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,800,000

89,000

'

'

Interest Expense

173,000

182,000

525,000

554,000

'

'

'

'

'

'

'

'

'

172,000

181,000

522,000

551,000

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

871,000

Line of Credit Facility, Collateral

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'$871,000

'

Note_7_Lease_Inducements_Detai1

Note 7 - Lease Inducements (Details) - Summary of Lease Inducements (CAD)	Sep. 30, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Current Portion	'		'
Lease Incentive Payable, Current	171		173
Repayable leasehold improvement allowance [iii]	402	[1]	370	[1]
Total Current Portion	573		543
Long-Term Portion	'		'
Lease Incentive Payable, Noncurrent	1,408		1,535
Repayable leasehold improvement allowance [iii]	5,777	[1]	6,082	[1]
Total Long-Term Portion	7,185		7,617
Total	7,758		8,160
Rent-free Inducement [Member]	'		'
Current Portion	'		'
Lease Incentive Payable, Current	56	[2]	58	[2]
Long-Term Portion	'		'
Lease Incentive Payable, Noncurrent	452	[2]	493	[2]
Non-repayable Leasehold Improvement Allowance [Member]	'		'
Current Portion	'		'
Lease Incentive Payable, Current	115	[3]	115	[3]
Long-Term Portion	'		'
Lease Incentive Payable, Noncurrent	956	[3]	1,042	[3]
[1]	The Company received a repayable leasehold improvement for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the three and nine month periods ended September 30, 2013 amounted to $94,000 and $274,000 [2012 - $84,000 and $245,000]. Interest payments for the three and nine month periods ended September 30, 2013 amounted to $172,000 and $522,000 [2012 - $181,000 and $551,000].
[2]	In 2007, the Company entered into a long-term facility lease agreement that included an eight and one half month rent-free period from May 17, 2007 to February 1, 2008. The lease inducement benefit arising from the rent-free period is being amortized on a straight-line basis over the term of the operating lease as a reduction to rental expense. Amortization for the three and nine month periods ended September 30, 2013 amounted to a reduction of rental expense $14,000 and $41,000 [2012 - $14,000 and $41,000].
[3]	The Company received a non-repayable allowance for an amount of $1.7 million for expenditures related to general upgrades to the facility. The lease inducement benefit arising from the non-repayable leasehold improvement allowance is being amortized on a straight-line basis over the balance of the term of the lease beginning April 1, 2008 as a reduction to rental expense. Amortization for the three and nine month periods ended September 30, 2013 amounted to a reduction of rental expense of $29,000 and $86,000 [2012 - $29,000 and $86,000].

Note_8_Share_Capital_and_Addit2

Note 8 - Share Capital and Additional Paid-in Capital (Details) (CAD)

1 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

12 Months Ended

Dec. 29, 2011

Sep. 30, 2013

Dec. 29, 2011

Dec. 31, 2011

Dec. 31, 2016

Jun. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2011

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 29, 2011

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2011

Restricted Stock Units (RSUs) [Member]

Warrant [Member]

Equity Option [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

2008 Plan [Member]

Deferred Share Unit Plan [Member]

Shareholders' Equity [Member]

Note 8 - Share Capital and Additional Paid-in Capital (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares, Issued

4,506,395

'

4,506,395

'

'

'

'

'

'

'

'

'

6,453,873

6,577,664

6,455,206

'

'

'

'

'

'

'

Warrant Exercise Price Per Whole Common Share (in Dollars per share)

1.492

'

1.492

'

1.492

1.492

'

'

'

'

'

'

'

'

'

1.492

'

'

'

'

'

'

Proceeds from Issuance of Common Stock (in Dollars)

6,723,542

'

'

'

'

'

'

'

'

'

'

'

2,330,921

'

'

'

'

3,706,882

'

'

'

6,037,803

Fair Value Assumptions, Risk Free Interest Rate

'

'

1.18%

'

'

'

'

'

'

'

'

'

'

'

'

1.69%

1.33%

'

'

'

'

'

Fair Value Assumptions, Expected Volatility Rate

'

'

110.00%

'

'

'

'

'

'

'

'

'

'

'

'

132.00%

128.00%

'

'

'

'

'

Payments of Stock Issuance Costs (in Dollars)

'

'

'

685,739

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative Liability, Current (in Dollars)

'

9,191,000

'

'

'

'

3,699,000

'

'

'

'

'

'

'

'

'

'

'

4,127,888

'

'

'

Payment of Financing and Stock Issuance Costs (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

421,008

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

'

'

'

'

'

'

'

164,441

'

'

'

'

'

'

'

'

'

'

'

1,315,532

164,441

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

'

'

'

'

'

'

'

111,183

'

'

'

'

'

'

'

'

'

'

'

172,763

'

'

Adjustments to Additional Paid in Capital, Share-based Compensation, Restricted Stock Unit or Restricted Stock Award, Requisite Service Period Recognition (in Dollars)

'

135,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)

'

913,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'

'2 years 94 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount

'

'

'

'

'

'

'

'

86,103,744

1,142,769

53,258

969,000

'

'

'

'

'

'

'

'

'

'

Note_8_Share_Capital_and_Addit3

Note 8 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Activity (CAD)	9 Months Ended
	Sep. 30, 2013
Stock Options, Activity [Abstract]	'
Balance	989,064
Balance (in Dollars per share)	1.98
Options granted	207,670
Options granted (in Dollars per share)	3.09
Options forfeited	-53,402
Options forfeited (in Dollars per share)	2.24
Options expired	-563
Options expired (in Dollars per share)	133.49
Balance	1,142,769
Balance (in Dollars per share)	2.11

Note_8_Share_Capital_and_Addit4

Note 8 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding (CAD)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
			Range One [Member]	Range Two [Member]	Range Three [Member]	Range Four [Member]	Range Five [Member]	Range Six [Member]
Note 8 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]	'	'	'	'	'	'	'	'
Range of exercise price, lower	'	'	1.02	'	3	6.8	23	1.02
Range of exercise price, upper	'	'	1.6	2.2	3.1	8.2	24	24
Number of shares under option	'	'	'8 years 328 days	'8 years 186 days	'9 years 171 days	'2 years 127 days	'295 days	'8 years 299 days
Weighted average remaining contractual life (in Shares)	1,142,769	989,064	509,316	430,878	198,270	2,036	2,269	1,142,769
Weighted average exercise price	2.11	1.98	1.53	2.2	3.09	7.75	23.38	2.11
Number of options currently exercisable (in Shares)	'	'	143,557	343,138	'	666	1,782	489,143
Weighted average exercise price	'	'	1.57	2.2	'	7.86	23.48	2.1

Note_8_Share_Capital_and_Addit5

Note 8 - Share Capital and Additional Paid-in Capital (Details) - Share-based Payment Award, Stock Options, Valuation Assumptions (CAD)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]	'	'
Risk-free interest rates	1.66%	1.69%
Expected dividend yield	0.00%	0.00%
Expected life (in years)	'5 years 270 days	'5 years 346 days
Expected volatility	123.00%	113.00%
Fair value per stock option (in Dollars per share)	2.68	1.59

Note_8_Share_Capital_and_Addit6

Note 8 - Share Capital and Additional Paid-in Capital (Details) - Restricted Share Unit Plan (CAD)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Note 8 - Share Capital and Additional Paid-in Capital (Details) - Restricted Share Unit Plan [Line Items]	'	'
Balance (in Dollars per share)	2.11	1.98
RSUs granted (in Dollars per share)	3.09	'
Restricted Stock Units (RSUs) [Member]	'	'
Note 8 - Share Capital and Additional Paid-in Capital (Details) - Restricted Share Unit Plan [Line Items]	'	'
Balance	53,258	0
Balance (in Dollars per share)	2.54	0
RSUs granted	53,258	'
RSUs granted (in Dollars per share)	2.54	'

Note_8_Share_Capital_and_Addit7

Note 8 - Share Capital and Additional Paid-in Capital (Details) - Allocation of Stock-based Compensation, by Type of Cost (CAD)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Share based compensation expense	190	89	506	492
Cost of Sales [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Share based compensation expense	8	3	24	19
Research and Development Expense [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Share based compensation expense	12	8	34	38
General and Administrative Expense [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Share based compensation expense	160	75	422	430
Selling and Marketing Expense [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Share based compensation expense	10	3	26	5

Note_8_Share_Capital_and_Addit8

Note 8 - Share Capital and Additional Paid-in Capital (Details) - Warrants Activities (Warrant [Member], CAD)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Warrant [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Number of warrants	86,103,744	89,976,289
Weighted average exercise price (in Dollars per share)	0.0746	0.0746
Exercise of warrants	-3,872,545	'
Exercise of warrants (in Dollars per share)	0.0746	'

Note_8_Share_Capital_and_Addit9

Note 8 - Share Capital and Additional Paid-in Capital (Details) - Estimated Fair Value of Warrants Issued (CAD)	12 Months Ended	9 Months Ended	12 Months Ended
	Dec. 29, 2011	Sep. 30, 2013	Dec. 31, 2012
		Warrant [Member]	Warrant [Member]
Note 8 - Share Capital and Additional Paid-in Capital (Details) - Estimated Fair Value of Warrants Issued [Line Items]	'	'	'
Risk-free interest rates	1.18%	1.69%	1.33%
Expected dividend yield	'	0.00%	0.00%
Expected life (in years)	'	'3 years 3 months	'4 years
Expected volatility	110.00%	132.00%	128.00%
Fair value of warrant (in Dollars per share)	'	0.1067	0.0411

Note_9_Related_Party_Transacti1

Note 9 - Related Party Transactions (Details) (Director [Member], CAD)	3 Months Ended	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2012
Director [Member]	'	'
Note 9 - Related Party Transactions (Details) [Line Items]	'	'
Professional Fees	25,000	100,000

Note_10_Commitments_Details

Note 10 - Commitments (Details)

3 Months Ended

9 Months Ended

180 Months Ended

3 Months Ended

9 Months Ended

45 Months Ended

3 Months Ended

9 Months Ended

24 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Jan. 31, 2023

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2009

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Jun. 30, 2007

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

CAD

CAD

CAD

CAD

CAD

Total License Fee Payment [Member]

Total License Fee Payment [Member]

Total License Fee Payment [Member]

Total License Fee Payment [Member]

Total License Fee Payment [Member]

Total License Fee Payment [Member]

Developed Technology Rights [Member]

Developed Technology Rights [Member]

Developed Technology Rights [Member]

Developed Technology Rights [Member]

Developed Technology Rights [Member]

Total License Fee Payment [Member]

West Nile Virus [Member]

West Nile Virus [Member]

West Nile Virus [Member]

CAD

CAD

CAD

CAD

USD ($)

USD ($)

CAD

CAD

CAD

CAD

CAD

CAD

CAD

CAD

CAD

Note 10 - Commitments (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty Expense

'

'

'

'

'

5,000

5,000

15,000

15,000

'

'

101,000

189,000

471,000

416,000

2,000,000

12,000

4,000

47,000

33,000

Royalty Guarantees, Commitments, Amount (in Dollars)

'

'

'

'

'

'

'

'

'

'

85,000

'

'

'

'

'

'

'

'

'

Quarterly License Fee Payment (in Dollars)

'

'

'

'

'

'

'

'

'

5,000

'

'

'

'

'

'

'

'

'

'

Total Monthly Payment to Landlord

'

'

'

'

170,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating Leases, Rent Expense, Net

201,000

196,000

606,000

583,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Commitment, Remaining Minimum Amount Committed

1,084,000

'

1,084,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_11_Segment_Information_De

Note 11 - Segment Information (Details) (CAD)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Customer A [Member] | Sales [Member]	'	'	'	'
Note 11 - Segment Information (Details) [Line Items]	'	'	'	'
Concentration Risk, Percentage	71.00%	75.00%	46.00%	'
Customer A [Member]	'	'	'	'
Note 11 - Segment Information (Details) [Line Items]	'	'	'	'
Revenues (in Dollars)	1,500,000	2,000,000	3,800,000	0.66
Two Customers [Member] | Sales [Member]	'	'	'	'
Note 11 - Segment Information (Details) [Line Items]	'	'	'	'
Concentration Risk, Percentage	'	'	61.00%	'
Two Customers [Member]	'	'	'	'
Note 11 - Segment Information (Details) [Line Items]	'	'	'	'
Revenues (in Dollars)	'	'	5,100,000	'
Minimum [Member] | Sales [Member]	'	'	'	'
Note 11 - Segment Information (Details) [Line Items]	'	'	'	'
Concentration Risk Threshold	'	'	10.00%	'

Note_11_Segment_Information_De1

Note 11 - Segment Information (Details) - Product Sales by Customer Location (CAD)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Note 11 - Segment Information (Details) - Product Sales by Customer Location [Line Items]	'	'	'	'
Product sales	2,088	2,679	8,397	8,699
China [Member]	'	'	'	'
Note 11 - Segment Information (Details) - Product Sales by Customer Location [Line Items]	'	'	'	'
Product sales	1,231	2,028	5,149	5,763
United States [Member]	'	'	'	'
Note 11 - Segment Information (Details) - Product Sales by Customer Location [Line Items]	'	'	'	'
Product sales	298	151	1,456	804
Asia (excluding China) [Member]	'	'	'	'
Note 11 - Segment Information (Details) - Product Sales by Customer Location [Line Items]	'	'	'	'
Product sales	107	27	466	620
Europe [Member]	'	'	'	'
Note 11 - Segment Information (Details) - Product Sales by Customer Location [Line Items]	'	'	'	'
Product sales	303	221	883	694
Canada [Member]	'	'	'	'
Note 11 - Segment Information (Details) - Product Sales by Customer Location [Line Items]	'	'	'	'
Product sales	4	11	33	27
Segment, Geographical, Groups of Countries, Group Three [Member]	'	'	'	'
Note 11 - Segment Information (Details) - Product Sales by Customer Location [Line Items]	'	'	'	'
Product sales	145	241	410	791

Note_11_Segment_Information_De2

Note 11 - Segment Information (Details) - Product Sales by Type of Product (CAD)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Segment Reporting Information [Line Items]	'	'	'	'
Product sales	2,088	2,679	8,397	8,699
Cardiovascular [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Product sales	1,852	2,559	7,088	8,012
Bio-defense Products [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Product sales	69	65	320	289
Infectious Diseases [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Product sales	1	'	456	47
West Nile Virus [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Product sales	166	55	533	351

Note_12_Contigencies_Details

Note 12 - Contigencies (Details) (CAD)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2009
					RAMP 200 Reader [Member]
Note 12 - Contigencies (Details) [Line Items]	'	'	'	'	'
Sales Revenue, Goods, Gross	2,088	2,679	8,397	8,699	900

Note_14_Subsequent_Events_Deta

Note 14 - Subsequent Events (Details) (Subsequent Event [Member], CAD)	0 Months Ended
In Millions, except Per Share data, unless otherwise specified	Nov. 07, 2013
Note 14 - Subsequent Events (Details) [Line Items]	'
Number of Subscription Receipts Issued, Private Placement	1,273,117
Sale of Stock, Price Per Share (in Dollars per share)	2.45
Proceeds from Issuance of Private Placement (in Dollars)	2.7
Gross [Member]	'
Note 14 - Subsequent Events (Details) [Line Items]	'
Proceeds from Issuance of Private Placement (in Dollars)	3.1
OrbiMed [Member]	'
Note 14 - Subsequent Events (Details) [Line Items]	'
Number of Subscription Receipts Issued, Private Placement	816,325
Proceeds from Issuance of Private Placement (in Dollars)	2